Novocure and the NYU Grossman School of Medicine’s Department of Radiation Oncology entered into a strategic alliance that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields.
On October 5, we virtually rang the opening bell at Nasdaq in Times Square in New York City in celebration of our 5-year anniversary of becoming a public company. Read more about our milestone of becoming a public company in 2015.
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.